Many of the latest anti-cancer drugs are targeted towards the tiniest molecular differences in cells. But even if you know the genetic make up of a tumour, getting medicines to - and then in to - the affected area is a different challenge.

Dr Moutih Rafei at Defence Therapeutics reports on a novel drug technology that gets more treatment to the cells that need it,  and what that might mean for the future of designing, trialling, and marketing medicines.

Read the original research: https://doi.org/10.1111/cas.15985